In ovarian and triple negative breast cancer cells, treatment with the DNA methyltransferase inhibitor 5-AZA-2-deoxycytidine activated MGAT5 transcription, resulting in increased migration and EMT [39], highlighting the potential side effects of epigenetic therapeutics in cancer treatment. The gene discussed is MGAT5; the disease is cancer.